SCHEMBL3436050

SCHEMBL3436050

CCCc1nc(-c2ccc(Cl)cc2OC)sc1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
MAPT P10636 1/20 0.44
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 1/20 0.41
CTSA P10619 5/20 0.39
MAPK1 P28482 1/20 0.39
PIK3CA P42336 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
MAPK10 P53779 1/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
DCLK1 O15075 1/20 0.39
FES P07332 1/20 0.39
PIM1 P11309 1/20 0.39
CDK2 P24941 1/20 0.39
GSK3A P49840 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10049077 0.91 KDM4E (0.46) KDM4EMAPTALDH1A1HPGDLMNA
SCHEMBL3436284 0.82 KDM4E (0.59) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL3436654 0.81 KDM4E (0.38) KDM4EMAPTALDH1A1LMNAMAPK1
SCHEMBL3435153 0.78 CRHR1 (0.43) KDM4EMAPTALDH1A1HPGDLMNA
SCHEMBL3435973 0.77 CCNT1 (0.43) CTSACDC7DBF4PTGDR2
SCHEMBL3437616 0.76 MAPT (0.61) KDM4EMAPTALDH1A1HPGDLMNA
SCHEMBL3843833 0.75 KDM4E (0.51) KDM4EMAPTALDH1A1NPC1POLB
SCHEMBL3435976 0.75 KDM4E (0.48) KDM4EMAPTALDH1A1NPC1POLB
SCHEMBL3435688 0.75 KDM4E (0.42) KDM4EMAPTALDH1A1HPGDLMNA
SCHEMBL3436683 0.74 KDM4E (0.40) KDM4EMAPTALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594555-B1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA PHARM CO LTD (JP) 2018-03-07 EP disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 US disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 US disclosed
EP-2594555-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA Pharmaceutical Co., Ltd. (JP) 2013-05-22 EP disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
WO-2012002527-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR あすか製薬株式会社 (JP) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR CDKN1A, SKP2, CCNI KDM4E 1069/4885MAPT 4033/4885ALDH1A1 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.